S. Garland

发表

Are GPCRs Still a Source of New Targets?

S. Garland, 2013, Journal of biomolecular screening.

Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design.

D. Gloriam, F. Blaney, S. Foord, 2009, Journal of medicinal chemistry.

GPCR Homology Model Development and Application

F. Blaney, S. Garland, 2010 .

What is the potential of G protein-coupled receptor [corrected] allosteric sites in drug design?

S. Garland, 2014, Future medicinal chemistry.

An industrial perspective on positive allosteric modulation as a means to discover safe and selective drugs.

S. Garland, M. Rocheville, Magalie Rocheville, 2010, Drug discovery today. Technologies.

2. G-Protein-Coupled Receptors

T. Heightman, S. Garland, 2008 .

Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74

M. Wigglesworth, D. Donnelly, D. Poyner, 2010, Biochemical and biophysical research communications.

The discovery of a selective, small molecule agonist for the MAS-related gene X1 receptor.

M. Wigglesworth, P. Szekeres, A. Muir, 2009, Journal of medicinal chemistry.

Design criteria for molecular mimics of fragments of the β-turn. 1. Cα atom analysis

Philip M. Dean, S. L. Garland, P. Dean, 1999, J. Comput. Aided Mol. Des..

5-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).

M. Saunders, J. Liddle, S. Garland, 2003, Bioorganic & medicinal chemistry letters.

Design criteria for molecular mimics of fragments of the β-turn. 2. Cα–Cβ bond vector analysis

Philip M. Dean, S. L. Garland, P. Dean, 1999, J. Comput. Aided Mol. Des..

Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine.

Michael A. Briggs, David M. Wilson, I. Wall, 2010, Bioorganic & medicinal chemistry letters.

4.26 – Seven Transmembrane G Protein-Coupled Receptors: Insights for Drug Design from Structure and Modeling

Frank E. Blaney, N. Barton, Stephen L. Garland, 2007 .

The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2.

Paul W Smith, Emma L. Koppe, C. Corti, 2010, Bioorganic & medicinal chemistry letters.

(1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: a novel class of potent MSK-1-inhibitors.

David M. Wilson, J. Witherington, S. Garland, 2005, Bioorganic & Medicinal Chemistry Letters.

Methods for the successful application of chemogenomics to GPCR drug design.

D. Gloriam, S. Garland, 2011, Current topics in medicinal chemistry.